Oncology Pharma Inc (ONPH) fair value: what the stock is really worth
As of Nov 18, 2026: fair value (intrinsic value) of Oncology Pharma Inc stock $0.03, price $0.04, that is 16.4% below the price, quality 39 out of 100. Rating: overvalued. Calculated from audited financials with 5 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Oncology Pharma Inc
ONPH · USExpensive (fair value 16% below the price) and weak company.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $0.0001 – $20.38 · the $0.0405 price screens above the $0.0338 fair value. As of Nov 16, 2026.
Every Wednesday you see whether Oncology Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus.
Show moreShow less
The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.
Stock analysis
Oncology Pharma Inc (ONPH) currently trades at $0.0405, while our model-based Fair Value estimate is $0.0338, 16% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $0.0600 per share, and 2 of the 5 models we run sit above the $0.0405 price.
Bear case: the Asset-Based group reads lowest at $0.0100, and 3 of the 5 models stay below the price. Data coverage for this calculation is low.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Financial Services sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Oncology Pharma Inc reported revenue of $10.2K in FY2013 versus $3.7M in FY2002, a compound −41.4%/yr. Reported net income was −$5.8K in FY2026.
Key figures
Market cap $3.3M Micro · EPS (TTM) $−0.2600 · Return on assets (EBIT) −1,189% (4-year average) · Operating margin −75.0% · Revenue (TTM) $10.2K · Free cash flow $369K · Net debt $658K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 70% below its 52-week high and 8,000% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at −51% fair-value upside, at −16%, ONPH screens cheaper than that median.
Fair Value models
All 5 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
ONPH screens overvalued: fair value 16% below the price. Compare with Vylor Inc →
Compare Oncology Pharma Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Shell Companies · 45 stocks
Valuation Multiplesvs Shell Companies median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Quality Score by industry
- Return on equity by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Shell Companies stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Metals Acquisition Corp MTAL | $10.13 | $17.26 | +70% | vs ONPH |
| AA Mission Acquisition Corp AAM | $0.0300 | $0.0390 | +30% | vs ONPH |
| Cantor Equity Partners I, Inc CEPO | $10.83 | $9.57 | −12% | vs ONPH |
| Lionheart III Corp LION | $13.83 | $9.72 | −30% | vs ONPH |
| Lionheart Holdings CUB | $10.96 | $5.41 | −51% | vs ONPH |
| Texas Ventures Acquisition III Corp TVACW | $0.1800 | $0.0850 | −53% | vs ONPH |
| Translational Development Acquisition Corp TDAC | $10.88 | $4.28 | −61% | vs ONPH |
| Berto Acquisition Corp TACO | $10.52 | $2.32 | −78% | vs ONPH |
| Vylor Inc VYLR | $69.82 | $14.24 | −80% | vs ONPH |
| Axiom Intelligence Acquisition Corp AXIN | $10.39 | $1.24 | −88% | vs ONPH |
Explore undervalued stocks
More undervalued Financial Services stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Oncology Pharma Inc (ONPH) overvalued or undervalued?
What is the fair value of ONPH?
What is the quality score of ONPH?
What is the price target for Oncology Pharma Inc (ONPH)?
What is the Oncology Pharma Inc stock forecast for 2026?
What is the revenue of Oncology Pharma Inc (ONPH)?
What growth is priced into Oncology Pharma Inc (ONPH)?
What discount rate (WACC) does the fair value of ONPH use?
What is a reverse DCF?
How much growth has Oncology Pharma Inc (ONPH) delivered so far?
How fast is the sector of Oncology Pharma Inc (ONPH) growing?
What is the free cash flow yield of Oncology Pharma Inc (ONPH)?
What is the intrinsic value of Oncology Pharma Inc (ONPH)?
Is Oncology Pharma Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ONPH?
How much is Oncology Pharma Inc worth?
How far is ONPH from its 52-week high?
Which stocks are comparable to Oncology Pharma Inc?
Is Oncology Pharma Inc stock attractive at the current price?
How is the fair value of ONPH calculated?
Is it still worth investing in stocks now?
What is the share price of Oncology Pharma Inc (ONPH)?
What should I pay attention to with Oncology Pharma Inc right now?
Key figures of Oncology Pharma Inc
How large is the market capitalisation of Oncology Pharma Inc (ONPH)?
What are the earnings per share of Oncology Pharma Inc (ONPH)?
What is the EBIT return on assets of Oncology Pharma Inc (ONPH)?
What is the operating margin of Oncology Pharma Inc (ONPH)?
How much net debt does Oncology Pharma Inc (ONPH) carry?
Watch Oncology Pharma Inc in the live analysis
One click puts Oncology Pharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.